Bristol-Myers Squibb (NYSE:BMY – Free Report) – Leerink Partnrs upped their FY2028 EPS estimates for Bristol-Myers Squibb in a report released on Tuesday, October 22nd. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will earn $6.40 per share for the year, up from their prior forecast of $6.24. The consensus estimate for Bristol-Myers Squibb’s current full-year earnings is $0.77 per share.
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) last issued its earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.43. The company had revenue of $12.20 billion during the quarter, compared to the consensus estimate of $11.54 billion. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. Bristol-Myers Squibb’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.75 EPS.
View Our Latest Research Report on BMY
Bristol-Myers Squibb Stock Performance
NYSE:BMY opened at $52.76 on Wednesday. The stock has a 50-day moving average price of $50.53 and a 200 day moving average price of $46.35. The company has a current ratio of 1.16, a quick ratio of 1.02 and a debt-to-equity ratio of 2.86. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $56.77. The stock has a market capitalization of $106.95 billion, a P/E ratio of -17.02, a P/E/G ratio of 13.75 and a beta of 0.46.
Bristol-Myers Squibb Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be paid a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.55%. Bristol-Myers Squibb’s dividend payout ratio is presently -77.42%.
Hedge Funds Weigh In On Bristol-Myers Squibb
Several hedge funds have recently added to or reduced their stakes in BMY. Global Assets Advisory LLC bought a new position in Bristol-Myers Squibb in the 1st quarter valued at $5,161,000. Sunbelt Securities Inc. lifted its holdings in Bristol-Myers Squibb by 19.1% during the 1st quarter. Sunbelt Securities Inc. now owns 10,080 shares of the biopharmaceutical company’s stock valued at $547,000 after buying an additional 1,614 shares in the last quarter. RMR Wealth Builders boosted its position in Bristol-Myers Squibb by 9.8% in the 1st quarter. RMR Wealth Builders now owns 5,805 shares of the biopharmaceutical company’s stock valued at $315,000 after buying an additional 517 shares during the period. Brookstone Capital Management grew its stake in Bristol-Myers Squibb by 36.4% in the 1st quarter. Brookstone Capital Management now owns 150,037 shares of the biopharmaceutical company’s stock worth $8,137,000 after acquiring an additional 40,018 shares in the last quarter. Finally, Future Financial Wealth Managment LLC bought a new stake in shares of Bristol-Myers Squibb during the first quarter valued at approximately $83,000. 76.41% of the stock is currently owned by institutional investors.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Featured Stories
- Five stocks we like better than Bristol-Myers Squibb
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
- Why Are Stock Sectors Important to Successful Investing?
- Short Sellers Eye Palantir: Should You Buy the Dip?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.